Julian Gangolli - GW Pharmaceuticals Executive Director

<div class='circular--portrait' style='background:#FF6600;color: #f7f7f7;font-size:4em;padding-top: 25px;;'>GP</div>
GWPH -- USA Stock  

USD 132.19  4.29  3.35%

Mr. Julian S. Gangolli is no longer President, North America of GW Pharmaceuticals PLC., effective May 10, 2019. Mr. Gangolli, was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1, 400person integrated commercial operation with sales exceeding 3.8 billion in 2014. As a Corporationrationrate Vice President and member of the Executive Committee, Allergan most senior leadership team overseeing worldwide operations, Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Prior to Allergan, Mr. Gangolli was Vice President, Sales and Marketing at VIVUS, Inc. where he established from inception a fully functioning commercial operation. Prior to VIVUS, Mr. Gangolli held roles at Syntex Pharmaceuticals, Inc. and OrthoCilag Pharmaceuticals Ltd. in the UK.
Age: 59  Director Since 2015      
(44) 1223 235667  www.gwpharm.com

Julian Gangolli Latest Insider Activity

GW Pharmaceuticals Management Efficiency

GW Pharmaceuticals Plc has return on total asset (ROA) of (5.79) % which means that it has lost $5.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.88 %, meaning that it created $4.88 on every $100 dollars invested by stockholders. GW Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to decrease to -17.2. The current Return on Average Assets is estimated to decrease to -0.01GW Pharmaceuticals Revenue to Assets are most likely to slightly decrease in the upcoming years. The last year's value of Revenue to Assets was reported at 0.0101. The current Total Assets Per Share is estimated to increase to 2.01, while Total Assets are estimated to decrease to roughly 884.4 M. The current Tax Liabilities is estimated to increase to about 619.8 K, while Total Liabilities is estimated to decrease to roughly 151.2 M.
The company currently holds 40.28 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 6.37, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives


Leslie BrunMerck Company
William PerezJohnson Johnson
Thomas GlocerMerck Company
Inge ThulinMerck Company
Philip BroadleyAstrazeneca PLC
Robert BertoliniBristol Myers Squibb
Andreas PlantaNovartis AG
Deryck MaughanGlaxoSmithKline PLC
Elizabeth DohertyNovartis AG
Marschall RungeEli Lilly And
Tim JacksonSmithAstrazeneca PLC
Karen VousdenBristol Myers Squibb
Craig ThompsonMerck Company
John MadiganGilead Sciences
Vicki SatoBristol Myers Squibb
Hans WijersGlaxoSmithKline PLC
Vindi BangaGlaxoSmithKline PLC
Jose GrasGrifols S A
Cornelia BargmannAstrazeneca PLC
Kevin LoftonGilead Sciences
David HooverEli Lilly And

Company Summary

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. GW Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 901 people.GW Pharmaceuticals Plc (GWPH) is traded on BATS Exchange in USA. It is located in Sovereign House Vision Park, Chivers Way Histon, Cambridge CB24 9BZ, United Kingdom and employs 901 people. GW Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

GW Pharmaceuticals Plc Leadership Team

William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

Stock Performance Indicators

Current Sentiment - GWPH

GW Pharmaceuticals Plc Investor Sentiment

Most of Macroaxis users are currently bullish on GW Pharmaceuticals Plc. What is your judgment towards investing in GW Pharmaceuticals Plc? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page